tqb2930 + paclitaxel

This combination consists of **TQB2930**, a monoclonal antibody immune checkpoint inhibitor targeting programmed death-ligand 1 (**PD-L1**), and **paclitaxel**, a chemotherapeutic agent that stabilizes microtubules to inhibit cell division. TQB2930 is being developed as an anti-cancer immunotherapy, and paclitaxel is a standard chemotherapeutic agent used for various malignancies. The combination is being studied for enhanced anti-tumor efficacy, particularly in recurrent or metastatic breast cancer, with TQB2930 potentially boosting the immune system's response against cancer, while paclitaxel exerts cytotoxic effects on rapidly dividing tumor cells[1].